Skip to main content
. 2018 Oct 8;8(10):e024144. doi: 10.1136/bmjopen-2018-024144

Table 1.

Migraine prevalence in different groups

Characteristics Sample Migraine (%) P values
Gender 0.022
 Male 169 29 (17.2)
 Female 170 49 (28.8)
Current age, years 0.039
 ≤16 82 12 (11.0)
 >16 257 66 (25.7)
Duration of epilepsy, years 0.001
 ≤10 235 42 (17.9)
 >10 104 36 (34.6)
Onset age, years 0.421
 ≤16 183 39 (21.3)
 >16 156 39 (25.0)
Seizure frequency in the last year 0.256
 0–12 246 56 (22.8)
 13–52 33 11 (33.3)
 >52 28 7 (25.0)
 Unknown 32 4 (12.5)
Number of AEDs 0.052
 ≤1 189 36 (19.0)
 ≥2 150 42 (28.0)
AEDs 0.299
 Topiramate 66 20 (30.3)
 Valproate 126 29 (23.0)
 Levetiracetam 94 26 (27.7)
 Oxcarbazepine 94 19 (20.2)
 Lamotrigine 27 2 (7.4)
 Carbamazepine 67 19 (28.4)
 Phenytoin 20 4 (20.0)
 Phenobarbital 12 2 (16.7)
Seizure types 0.319
 Focal onset seizure 68 10 (14.7)
 Generalised onset seizure and focal to bilateral tonic–clonic seizures 227 58 (25.6)
 Undetermined 44 10 (22.7)
Familial epilepsy 11 5 (45.5) 0.135
 First-degree relatives 9 4 (44.4)
 Second-degree relatives 2 1 (50.0)
 No familial epilepsy 328 73 (22.3)
Right-to-left shunt
 Grade 1 99 26 (26.3) 0.102
 Grade 2–3 41 16 (39.0) 0.003
 Grade 1–3 140 42 (29.6) 0.010
 Grade 0 199 36 (18.1)

AEDs, antiepileptic drugs.